Publications by authors named "Pietro Canetta"

BACKGROUNDIt is unknown whether the risk of kidney disease progression and failure differs between patients with and without genetic kidney disorders.METHODSThree cohorts were evaluated: the prospective Cure Glomerulonephropathy Network (CureGN) and 2 retrospective cohorts from Columbia University, including 5,727 adults and children with kidney disease from any etiology who underwent whole-genome or exome sequencing. The effects of monogenic kidney disorders and APOL1 kidney-risk genotypes on the risk of kidney failure, estimated glomerular filtration rate (eGFR) decline, and disease remission rates were evaluated along with diagnostic yields and the impact of American College of Medical Genetics secondary findings (ACMG SFs).

View Article and Find Full Text PDF

Introduction: Neural epidermal growth factor like 1 membranous nephropathy (NELL1 MN) is associated with various secondary etiologies. However, previous studies on the frequency of these associations and their impact on outcomes are limited. We report a large multiinstitutional series of patients with NELL1 MN with a focus on secondary associations, pathology findings, and their impact on outcome.

View Article and Find Full Text PDF

African Americans have a significantly higher risk of developing chronic kidney disease, especially focal segmental glomerulosclerosis -, than European Americans. Two coding variants (G1 and G2) in the APOL1 gene play a major role in this disparity. While 13% of African Americans carry the high-risk recessive genotypes, only a fraction of these individuals develops FSGS or kidney failure, indicating the involvement of additional disease modifiers.

View Article and Find Full Text PDF

Optimal supportive therapy with BP and proteinuria control is pivotal in treating patients with IgA nephropathy. Suboptimal treatment of hypertension and proteinuria persisted in many patients with IgA nephropathy in the Cure Glomerulonephropathy Network study. Many patients had above-target proteinuria despite optimal BP control and may benefit from novel therapies or clinical trials.

View Article and Find Full Text PDF
Article Synopsis
  • - A phase 3 trial investigated the long-term effects of sparsentan versus irbesartan in treating focal segmental glomerulosclerosis (FSGS) over 108 weeks, enrolling 371 patients aged 8 to 75.
  • - At 36 weeks, sparsentan showed a significantly higher rate of partial remission of proteinuria (42%) compared to irbesartan (26%), and this positive response continued up to 108 weeks.
  • - However, there were no significant differences in the estimated glomerular filtration rate (eGFR) slopes between the two groups at the final analysis, indicating that while proteinuria improved, kidney function as measured by eGFR remained similar with both treatments. *
View Article and Find Full Text PDF

Rationale & Objective: Some living donor kidneys are found to have biopsy evidence of chronic scarring and/or glomerular disease at implantation, but it is unclear if these biopsy findings help predict donor kidney recovery or allograft outcomes. Our objective was to identify the prevalence of chronic histological changes and glomerular disease in donor kidneys, and their association with donor and recipient outcomes.

Study Design: Retrospective cohort study.

View Article and Find Full Text PDF

Background: Hematuria is frequently present in podocytopathies, but its significance and prognostic value is not well described in these proteinuric kidney diseases. This study describes the prevalence and association between hematuria and kidney-related outcomes in these disorders.

Methods: Hematuria was assessed at the initial urinalysis in participants with the following podocytopathies-membranous nephropathy, minimal change disease, and FSGS-in the Nephrotic Syndrome Study Network and Cure Glomerulonephropathy cohorts with >24 months of follow-up.

View Article and Find Full Text PDF

Rationale & Objective: Patients with glomerular disease (GN) may be at increased risk of severe COVID-19, yet concerns over vaccines causing disease relapse may lead to vaccine hesitancy. We examined the associations of COVID-19 with longitudinal kidney function and proteinuria and compared these with similar associations with COVID-19 vaccination.

Study Design: Observational cohort study from July 1, 2021, to January 1, 2023.

View Article and Find Full Text PDF

Black Americans have a significantly higher risk of developing chronic kidney disease (CKD), especially focal segmental glomerulosclerosis (FSGS), than European Americans. Two coding variants (G1 and G2) in the gene play a major role in this disparity. While 13% of Black Americans carry the high-risk recessive genotypes, only a fraction of these individuals develops FSGS or kidney failure, indicating the involvement of additional disease modifiers.

View Article and Find Full Text PDF

Introduction: Lysozyme-associated nephropathy (LyN), a rare cause of kidney injury in patients with chronic myelomonocytic leukemia (CMML), has not been well described to date. We report the clinicopathologic spectrum of LyN from a multi-institutional series.

Method: We identified 37 native kidney biopsies with LyN and retrospectively obtained clinicopathologic data.

View Article and Find Full Text PDF
Article Synopsis
  • IgA nephropathy (IgAN) is a serious kidney disease linked to IgA buildup, and a large study identified 30 genetic risk factors associated with it.
  • Fourteen new loci were discovered that suggest a connection between genetic influences and abnormal IgA levels.
  • The research highlights inflammation-related pathways and potential drug targets, revealing that higher genetic risk scores are tied to earlier kidney failure.
View Article and Find Full Text PDF

Significance Statement: Congenital obstructive uropathy (COU) is a prevalent human developmental defect with highly heterogeneous clinical presentations and outcomes. Genetics may refine diagnosis, prognosis, and treatment, but the genomic architecture of COU is largely unknown. Comprehensive genomic screening study of 733 cases with three distinct COU subphenotypes revealed disease etiology in 10.

View Article and Find Full Text PDF
Article Synopsis
  • FSGS is a complex kidney disease with a poor outlook, linked to specific genetic changes in the APOL1 gene that may accelerate kidney failure.
  • This study analyzed data from patients with FSGS to understand how different genetic risk profiles (specifically APOL1 alleles) impact the progression of kidney disease.
  • Results showed that individuals with a high-risk APOL1 genotype experienced significantly faster declines in kidney function compared to those with lower risk, indicating a need for targeted patient care.
View Article and Find Full Text PDF

Rationale & Objective: Adolescent- and adult-onset minimal change disease (MCD) may have a clinical course distinct from childhood-onset disease. We characterized the course of children and adults with MCD in the Cure Glomerulonephropathy Network (CureGN) and assessed predictors of rituximab response.

Study Design: Prospective, multicenter, observational study.

View Article and Find Full Text PDF

Introduction: IgA nephropathy (IgAN) differs from other glomerular diseases by the frequently predominant lambda over kappa light chain deposition. Using the Cure Glomerulonephropathy (CureGN) IgAN cohort, we aimed to determine whether predominant lambda chain deposition is associated with worse clinical outcomes or histopathologic markers of more active disease.

Methods: Patients were categorized based on the intensity of light chain staining.

View Article and Find Full Text PDF
Article Synopsis
  • IgA nephropathy (IgAN) is a common kidney disease that can recur after transplantation, but its causes and outcomes are not well understood, prompting this study on the influence of HLA antigens.
  • The study analyzed 282 kidney transplant patients, noting that those with IgAN had different HLA antigen frequencies compared to healthy controls, but recurrent IgAN patients had similar frequencies to non-recurrent ones.
  • Younger age at transplantation and HLA-matching in living-related donors were linked to recurrent IgAN, which significantly worsened allograft survival alongside other factors like acute rejection and higher serum creatinine levels.
View Article and Find Full Text PDF
Article Synopsis
  • Relapse of nephrotic syndrome is common in primary membranous nephropathy (MN), but this study focuses on instances of late relapse occurring over 5 years after sustained remission.
  • The study analyzed data from Columbia University's Glomerular Kidney Disease Center and identified 16 patients who experienced late relapse, with an average time of 10.2 years in remission before relapse.
  • Results indicate that most patients had positive long-term kidney outcomes after late relapse, with 88% remaining in remission by the end of the study and only a slight decline in kidney function over time.*
View Article and Find Full Text PDF

Background: The long-term outcome of COVID-19-associated collapsing glomerulopathy is unknown.

Methods: We retrospectively identified 76 native kidney biopsies from patients with history of COVID-19 between March 2020 and April 2021. Presenting and outcome data were obtained for all 23 patients with collapsing glomerulopathy and for seven patients with noncollapsing podocytopathies.

View Article and Find Full Text PDF

We report a case of a 40-year-old woman who developed profound polyuria (>25 L urine output) immediately after initiation of venoarterial (VA) extracorporeal membrane oxygenation (ECMO). Investigations into the cause determined the polyuria was due to marked natriuresis (>85 g of sodium excreted in 1 day). This natriuresis persisted despite low cardiac filling pressures and high-negative ECMO venous pressures, suggesting clinical hypovolemia due to pressure natriuresis from locally high pressures at the renal artery due to arterial ECMO inflow.

View Article and Find Full Text PDF

Introduction: The pathologic approach to glomerulonephritis (GN) with fibrillar IgG deposits and light chain restriction remains a diagnostic challenge.

Method: All GN with fibrillar deposits of IgG and apparent light chain restriction on standard immunofluorescence on frozen tissue (IF-F) accessioned at the Columbia Renal Pathology Laboratory from 2012 to 2019 were identified. Additional studies including staining for Congo red, DNAJB9, IgG subtypes, and immunofluorescence on pronase-digested paraffin sections (IF-P) were performed.

View Article and Find Full Text PDF

Hydralazine, a widely used therapy for hypertension and heart failure, can elicit autoimmune disease, including anti-neutrophil cytoplasmic antibody associated glomerulonephritis (ANCA-GN). We identified 80 cases of ANCA-GN complicating treatment with hydralazine, accounting for 4.3% (80/1858 biopsies) of ANCA-GN diagnosed between 2006 and 2019.

View Article and Find Full Text PDF

Rationale & Objective: Anti-glomerular basement membrane (GBM) disease is a rapidly progressive glomerulonephritis which, in some instances, occurs concurrently with other diseases such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Rarely, it also occurs with membranous nephropathy (MN). We report a series of such patients, characterizing their long-term follow up.

View Article and Find Full Text PDF